Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.

Wang Y, Yu M, Yang JX, Cao DY, Yuan Z, Zhou HM, Zhang Y, Li L, Shen K, Wu H.

Int J Clin Oncol. 2019 Jun;24(6):712-720. doi: 10.1007/s10147-019-01404-2. Epub 2019 Feb 12.

PMID:
30746595
2.
4.

Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.

Giampaolino P, Di Spiezio Sardo A, Mollo A, Raffone A, Travaglino A, Boccellino A, Zizolfi B, Insabato L, Zullo F, De Placido G, Bifulco G.

J Minim Invasive Gynecol. 2019 May - Jun;26(4):648-656. doi: 10.1016/j.jmig.2018.07.001. Epub 2018 Jul 11.

PMID:
30017893
5.

Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.

Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L.

Int J Gynaecol Obstet. 2016 Jan;132(1):34-8. doi: 10.1016/j.ijgo.2015.06.046. Epub 2015 Oct 1.

PMID:
26493012
6.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004. Epub 2015 Jun 16.

PMID:
26092080
7.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020. Epub 2014 Feb 19.

PMID:
24561246
8.

Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D.

J Gynecol Oncol. 2018 Mar;29(2):e21. doi: 10.3802/jgo.2018.29.e21. Epub 2018 Jan 2.

9.

Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.

Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M.

Ann Oncol. 2016 Feb;27(2):262-6. doi: 10.1093/annonc/mdv539. Epub 2015 Nov 16.

PMID:
26578736
10.

[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].

Cao DY, Yu M, Yang JX, Shen K, Huang HF, Cheng NH, Sun ZY, Deng CY, Yu Q, He FF.

Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Chinese.

PMID:
24284224
11.

Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.

Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M.

Ann Oncol. 2011 Mar;22(3):643-9. doi: 10.1093/annonc/mdq463. Epub 2010 Sep 28.

PMID:
20876910
12.

Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.

Gonthier C, Walker F, Luton D, Yazbeck C, Madelenat P, Koskas M.

Gynecol Oncol. 2014 Apr;133(1):33-7. doi: 10.1016/j.ygyno.2013.11.007.

PMID:
24680589
13.

Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.

Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, Wang Z, Zhao C, Wei L.

Gynecol Oncol. 2015 Dec;139(3):424-8. doi: 10.1016/j.ygyno.2015.09.078. Epub 2015 Sep 30.

PMID:
26428941
14.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review.

PMID:
25118836
15.

Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.

Park JY, Lee SH, Seong SJ, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Gynecol Oncol. 2013 Apr;129(1):7-11. doi: 10.1016/j.ygyno.2012.12.037. Epub 2012 Dec 30.

PMID:
23283299
16.

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, Xie B, Shi Y, Luo X, Zhang H, Chen X.

Gynecol Oncol. 2019 Apr;153(1):55-62. doi: 10.1016/j.ygyno.2019.01.014. Epub 2019 Jan 21.

17.

Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.

Pronin SM, Novikova OV, Andreeva JY, Novikova EG.

Int J Gynecol Cancer. 2015 Jul;25(6):1010-4. doi: 10.1097/IGC.0000000000000467.

PMID:
25950126
18.

Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.

Kataoka H, Mori T, Yamamoto T, Sawada M, Kuroboshi H, Tatsumi H, Iwasaku K, Kitawaki J.

Eur J Gynaecol Oncol. 2014;35(1):11-5.

PMID:
24654454
19.

[Fertility-sparing management of endometrial cancer and atypical hyperplasia].

Gonthier C, Trefoux-Bourdet A, Luton D, Koskas M.

Gynecol Obstet Fertil Senol. 2017 Feb;45(2):112-118. doi: 10.1016/j.gofs.2016.12.011. Epub 2017 Jan 26. French.

PMID:
28368791
20.

Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.

Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M.

Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1934-7.

Supplemental Content

Support Center